Annual report [Section 13 and 15(d), not S-K Item 405]

Description of Business, Organization and Liquidity - Additional Information (Details)

v3.25.1
Description of Business, Organization and Liquidity - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 13, 2024
Dec. 31, 2024
Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Merger agreement closing date Dec. 13, 2024    
Conversion of preferred stock 4,753,650 13.34  
Net Income (Loss)   $ (17,434) $ 18,691
Net cash used in operating activities   (10,840) (13,703)
Accumulated deficit   (93,735) (76,301)
Common Stock [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Conversion of stock, shares converted 1,179,163    
Net Income (Loss)   $ 0 $ 0
Prefund Warrants [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Conversion of stock, shares converted 168,503    
Palvella Therapeutics, Inc [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Conversion of common stock 1,770,167    
Exchange ratio $ 0.309469242    
Pipe Financing [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Aggregate purchase price of prefunded warrants $ 60,000    
Stockholders owned voting rights percentage 60.00%    
Pipe Financing [Member] | Common Stock [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Conversion of stock, shares converted 1,988,885    
Pipe Financing [Member] | Prefund Warrants [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Conversion of stock, shares converted 2,297,953